Clinical trial

Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94

NCT00617032

Study summary

ClinicalTrials.gov

Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

GENETIC · Unmapped registry intervention tgAAC94 gene therapy vector Find medicine records · Find other trials using this name

GENETIC · Unmapped registry intervention tgAAC94 placebo Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2004-02-01

PhasePHASE1

Conditions

Rheumatoid Arthritisverified · MONDO: rheumatoid arthritis

Interventions

tgAAC94 gene therapy vectorGENETIC

tgAAC94 placeboGENETIC

Sponsors & collaborators

Targeted Genetics Corporationlead sponsor

Mapped research locations

TorontoOntario, Canada2 Los AngelesCalifornia, United States1 SeattleWashington, United States1 DenverColorado, United States1 VancouverBritish Columbia, Canada1 WinnipegManitoba, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00617032 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.